Inve India ▾

Morepen Laboratories share price & results

Morepen Laboratories Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q4 FY25
Ownership as of
Sept 2026

Indian API maker and consumer-health company: bulk drugs, branded formulations, and diagnostic devices.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue678 ₹ crore+83.2% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin16.0 %+8.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit78.0 ₹ crore+457.1% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity15.72 %−6.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-7.03 %+3.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)30.13 %−7.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

3 of 7 judged targets kept · 8 open · verdicts reflect calls analysed to Q4 FY25.

Morepen Laboratories Limited management guidance track record on Inve: 15 targets tracked across analysed earnings calls (3 achieved, 4 missed, 8 open).

TargetOriginal wordingSaidLatest callVerdict
Medical Devices RevenueINR 540-545 crores for FY25
Call transcript, Q2 FY25 · 12 Nov 2024		Q2 FY25Q4 FY25:Achieved INR 496 crores, beating the revised target but missing the original.
Call transcript, Q4 FY25 · 17 May 2025		Achieved*
Overall Revenue Growth15-20% for FY25
Call transcript, Q1 FY25 · 14 Aug 2024		Q1 FY25Q4 FY25:Achieved 7.4% growth in FY25, explicitly stating it was 'lower than expected'.
Call transcript, Q4 FY25 · 17 May 2025		Missed
Glucometer CapacityIncrease from 2.5 million to 5 million in 12-18 months
Call transcript, Q1 FY25 · 14 Aug 2024		Q1 FY25Q4 FY25:Revised target down to 3.6 million units.
Call transcript, Q4 FY25 · 17 May 2025		Revised Down

Source: Inve Guidance Tracker for Morepen Laboratories Limited · to Q4 FY25

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Morepen Laboratories Limited's 15 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹126.01 +2.00% · +₹2.47

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +158.0% 1Y

₹50₹100₹150Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹48.84 on 24 Oct 2025 → ₹126.01. High ₹146.97 (7 Oct 2026), low ₹33.68 (30 Mar 2026).

Previous close
₹123.54
Market cap
₹7.2k Cr
52-week range
₹33.68 – ₹146.97
One year
+159.98%
Price to earnings (TTM to Sept 2026)
38.20×
Return on equity (TTM to Sept 2026)
15.72%

Overview

Symbol
NSE:MOREPENLAB
Exchange
NSE
Currency
INR

What Morepen Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Morepen Laboratories manufactures Active Pharmaceutical Ingredients (APIs) at its Baddi (Himachal Pradesh) and Masulkhana integrated pharma complexes, exporting to regulated and non-regulated generic-drug makers worldwide, and has recently added a CDMO (contract development & manufacturing) business under long-duration supply programs with global pharma customers. It also sells branded prescription formulations (via its Cardia and Medicus divisions) and OTC consumer-health products under the Dr. Morepen brand through hospitals, doctors, pharmacies and retail chains in India. A third business, Medical Devices, designs and manufactures home-diagnostic products such as glucometers and blood-pressure monitors sold through pharmacy, retail and e-commerce channels.

Segments

  • API (Active Pharmaceutical Ingredients)
  • Formulations & OTC
  • Medical Devices
Manufacturing facilities
Two integrated API/formulation complexes — Baddi (Himachal Pradesh) and Masulkhana — both USFDA and EU (EDQM) approved
Export presence
90+ countries
Market leadership
Market leader in 6 key APIs — loratadine, desloratadine, montelukast, atorvastatin, rosuvastatin and fexofenadine
Global regulatory filings
403 Global DMF filings
Installed API manufacturing capacity
~500 KL production base (existing)
Regulatory track record
4 consecutive USFDA inspections with nil 483 observations
Founded 1985Headquarters Gurugram, Haryana (Corporate Office); Baddi, Himachal Pradesh (Registered Office) Company website

Your own record

Start an Inve Case for Morepen Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Morepen Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Morepen Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.